

7 October 2026

ASX Announcement

Firebrick Investor Update Presentation

- Investor presentation with important details on the Company's recently announced US retail plan for Nasodine Nasal Spray

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is pleased to release an investor update presentation, highlighting the US retail plans for Nasodine Nasal Spray and future Nasodine products.

The presentation emphasises the US market's potential financial returns for Firebrick through license fees on US sales.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick Pharma

Firebrick Pharma is commercialising Nasodine® Nasal Spray (0.5% PVP-I), which has already been introduced into several markets. It was also recently approved for marketing in Indonesia, and approval in the Philippines is expected. Nasodine® Throat Spray is the first follow-on product in the Nasodine range and is now available in Singapore and soon in the US. Importantly in the US, Firebrick is now expanding from online sales only to actively pursuing retail pharmacy distribution. For further information, visit firebrickpharma.com

Investor contact: Kam Watson, Firebrick Pharma; investors@firebrickpharma.com



AUSSIE EQUITIES DAY

Singapore, 9 October 2026

Sponsored by Spark+

Peter Molloy

Executive Chairman

ASX: FRE

firebrickpharma.com

Authorised for release by the
Executive Chairman of Firebrick Pharma Limited



Singapore Pack



USA Pack

IMPORTANT NOTICE AND DISCLAIMER

This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared as of its date, and remains subject to change without notice. This presentation has been provided to you solely for the purpose of giving you background information about Firebrick Pharma Limited (**Firebrick**). This presentation is intended only for those persons to whom it is delivered personally by or on behalf of Firebrick. By attending this presentation, you represent and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document (as defined in the Corporations Act 2001 (Cth) (**Corporations Act**)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are outside Australia, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this document and any copies and do not provide this document to any other person. This presentation is strictly confidential and is intended for the exclusive benefit of the person to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Firebrick. The recipient shall not disclose any of the information contained in this presentation to any other person without the prior written consent of Firebrick, which may be withheld in its absolute discretion.

No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. Neither Firebrick, its related bodies corporate, shareholders or affiliates, nor any of their respective officers, directors, employees, related bodies corporate, affiliates, agents or advisers makes any representations or warranties that this presentation is complete or that it contains all material information about Firebrick or which a prospective investor or purchaser may require in evaluating a possible investment in Firebrick or an acquisition of its shares. To the maximum extent permitted by law, none of those persons accept any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based upon information known and assumptions made as of the date of this presentation. Forward looking statements can generally be identified by the use of forward looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance or outlook on, clinical trials, required regulatory approvals, future earnings or financial position or performance are also forward looking statements. These statements are subject to internal and external risks and uncertainties that may have a material effect on future business. Actual results may differ materially from any future results or performance expressed, predicted or implied by the statements contained in this presentation. As such, undue reliance should not be placed on any forward looking statement. Past performance is not necessarily a guide to future performance. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future. No person is under any obligation to update this presentation at any time after its release to you.

The provision of this presentation is not a representation to you or any other person that an offer of securities will be made. Any prospective transaction would be undertaken solely on the basis of disclosure documentation prepared in accordance with applicable securities laws and regulations. The information presented in this presentation may differ materially in both content and presentation from that presented in any disclosure document prepared in connection with any prospective transaction. Firebrick reserves the right to alter the information contained in this presentation in any disclosure document prepared in respect of any prospective transaction from the form of this presentation accordingly.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in Firebrick and neither this presentation nor any of the information contained herein shall form the basis of any contract or commitment. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

This presentation may not be reproduced or redistributed to any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party without the prior approval of Firebrick. All references to dollars, cents or \$ in this presentation are to Australian currency, unless otherwise stated.

In receiving this presentation, each recipient agrees to the foregoing terms and conditions.

Capital Structure Overview

Financial Information (ASX: FRE) A\$	
Share price (52-week range)	\$0.024-0.070
Shares on Issue	285.2m
Market cap (1 Oct 2026)	\$8.0m
Cash balance (30 Jun 2026)	\$1.32m
Quarterly burn (FY26 average)	\$0.65m

Major shareholders (1 Oct 2026)	
P Molloy (CEO, Chairman)	11.2%
S Goodall (COO, Director)	10.9%
GZ Family Holdings (Family Office)	8.5%
Pharma Nutria Inc (Licensee/Strategic Investor)	4.5%
Top 10	47%



Product Overview:

Nasodine[®] Nasal Spray

(povidone-iodine 0.5%)



The rationale for a PVP-I nasal spray

- Povidone-iodine (PVP-I) is a well-established topical antiseptic (most widely marketed widely under BETADINE* brand)
- PVP-I kills all respiratory viruses and has no resistance potential (unlike antivirals or vaccines)
- Firebrick mission: create a safe and easy-to-use PVP-I nasal spray for the prevention and treatment of the common cold
- Potential breakthrough: The first common cold product that actually targets the viral cause
- Firebrick has patented the use of PVP-I for treatment and prevention of common cold



* BETADINE is a registered trademark of Mundipharma and is not associated with Nasodine or Firebrick Pharma

Nasodine[®]

Nasal Spray

- The world's **first nasal spray that kills germs**, including all viruses and bacteria that cause nasal infections
 - Including all pandemic viruses tested
 - No evident potential for viral or bacterial resistance
- A **nasal sanitiser/antiseptic** for:
 - **Protection against airborne viruses** when people around you have symptoms
 - **Front line pandemic defence** for healthcare workers
 - **Airlines, cruise lines and every business** that wants to reduce transmission risk
 - **Air travellers, commuters, doctors, hospitals, teachers, mothers** and anyone else worried about airborne germs
 - **Early treatment of the Common Cold**



Singapore Retail Packaging

Backed by science and published clinical trials

(and not dependent on future clinical trial outcomes)




- Backed by Science
 - 10 years of R&D
 - Published (open access) clinical trials
 - Granted international patents
 - R&D phase is behind us, now commercialising
- The market need
 - Developed as a treatment for the Common Cold
 - Post-pandemic, opportunity also as a nasal sanitiser
- Now in early commercialisation
 - Commercially manufactured, sold in a few markets currently
- Business model
 - Generate license fees from sales through licensees in SE Asia and in the USA to make FRE profitable

The strategy in SE Asia


Singapore	- Nasodine Nasal Spray launched Jun-24; first country in Asia; key test market for Nasodine and regional hub for business development - Premium pricing in the region, but relatively small population and sales potential (FY26 sales were ~3,700 units) - Jan-26: Announced 2nd product in range Nasodine Throat Spray
Indonesia	- Largest market (by population) in SEA - Nasodine Nasal Spray approved for marketing; launch in FY27 - Large sales volume potential, but low price
Philippines	- Licensing partner in place (SV More Pharma), who is also a strategic investor in FRE - Local manufacturing successfully established, regulatory application in process, awaiting marketing approval
SEA overall Strategy	- Focus on major markets, with regional manufacturing hub - We operate exclusively through licensing partners who fund all marketing - License fees approx. A\$2.50 per unit sold*; 1 million units for FRE to be cash flow positive based on the Company's current cost base

* Estimate based on Philippines license agreement; average license fees in other markets may be lower



Strategy in the US

- Nasodine Nasal Spray can be marketed as a cosmetic 'nasal cleanser' without pre-approval by FDA
- Nasodine has been available online only in the US since mid-2024 Through dedicated website and one online pharmacy partner
 - Nasodine.com has more than 1,000 customers across 50 US states
 - Consistent 5-star reviews, repurchases; FY26 sales growth = 230%
 - Unit sales are modest (7,000 in FY26) but enough to cover US costs
 - Consumer attractiveness of Nasodine clearly established by the online business
- 2026: Expand to the much larger retail (drugstore) market
 - Action: Present Nasodine at #1 US retail pharmacy trade expo
 - Goal: assess whether retail buyers will support Nasodine



NACDS Annual Expo, Boston 15-17 August 2026

(NACDS = National Association of Chain Drugstores)

- Annual meeting of retail buyers and decision-makers from
 - Independent drugstore groups
 - Wholesale banner groups
 - Major retail chains
 - Representing up to 50,000 drugstores across US
- Firebrick had 20 scheduled meetings with retailers, sampled extensively, advertised, and exhibited in the trade show
- Take home messages:
 - Retail market was positive about Nasodine: An attractive new entrant in the emerging (post-COVID) category of 'nasal health'
 - Positive that it's backed by real science and clinical studies
 - Positioning as a *cosmetic* nasal cleanser not a limitation
 - Six independent drugstore groups (representing around 700 stores) expressed strong intent to place early orders
 - We should introduce the throat spray and other new products as soon as possible in the US, to give them a portfolio of Nasodine products to support



Al Moghaddam and Peter Molloy at NACDS



Nasodine trade exhibit at NACDS

Nasodine[®]

NASAL SPRAY

Daily nasal cleanser to help maintain nasal health

For informed, health-conscious consumers in a post-COVID world

Ideal for:

- Daily nasal hygiene
- Air travel
- Commuting
- Crowds
- Offices

Nasal mist & cleanser

Nasodine[®]
Povidone-Iodine

Helps cleanse:

- ✓ Germs
- ✓ Viruses
- ✓ Bacteria
- ✓ Irritants

25 mL (0.85 oz)

The Nasal Spray backed by real Science:

- Result of 10 years of R&D and backed by multiple patents
- Safety consistently proven in controlled human trials
- Studies published in open access peer-reviewed journals
- Tamper resistant integrated pump and bottle
- Ready to use, no assembly, no mess

✓ Retail-ready 25 mL pack

✓ For adults and children 12+

✓ GMP Manufactured in USA


Visit us at Booth 1447

nasodine.com

Full Page Advertisement in Chain Drugstore Industry News

Firebrick announcement 29 Sep 2026: USA Retail Launch Plan


- Nasodine Nasal Spray to become available in US retail drugstores in 2027
- Three phase expansion process, starting with independent pharmacy groups
- Potential for early orders from independent drugstore groups
- US Commercial Director appointed to drive drugstore sales: retainer + 3% on sales
- Scaling up US manufacturing to meet expected retail volume



What does this mean for Firebrick Pharma?

Potential to fully fund the company from US License Fees

- Firebrick (ASX: FRE) receives license fees from the US entity (Firebrick Pharma, Inc.):
 - 12% royalty on sales
 - 20% manufacturing license fee on COGS (equiv. to approx. 6% on sales)
 - 5% management fee on sales
- Aggregate license fees could amount to around A\$4.00 per unit
 - 60% greater than potential SE Asia license fees
 - US sales could fully fund Firebrick (FRE) with up to 700,000 units sold p.a.



* Rates as agreed in the license agreement between FRE and the US licensee, Firebrick Pharma, Inc. Manufacturing License Fee will vary based on actual COGS

Investor summary

- US retail opportunity is a 'game-changer' for Firebrick
- Combined with Asian license fees, the US could significantly accelerate positive cash flows for FRE
- US market will become a focus for Firebrick and source for significant future news flow





For more information:
www.firebrickpharma.com

ASX: FRE

